ORCID Profile
0000-0001-9129-8057
Current Organisations
Qassim University
,
National Cancer Center Hospital
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: MDPI AG
Date: 18-03-2022
DOI: 10.3390/EN15062243
Abstract: Incorporating solar energy into a grid necessitates an accurate power production forecast for photovoltaic (PV) facilities. In this research, output PV power was predicted at an hour ahead on yearly basis for three different PV plants based on polycrystalline (p-si), monocrystalline (m-si), and thin-film (a-si) technologies over a four-year period. Wind speed, module temperature, ambiance, and solar irradiation were among the input characteristics taken into account. Each PV plant power output was the output parameter. A deep learning method (RNN-LSTM) was developed and evaluated against existing techniques to forecast the PV output power of the selected PV plant. The proposed technique was compared with regression (GPR, GPR (PCA)), hybrid ANFIS (grid partitioning, subtractive clustering and FCM) and machine learning (ANN, SVR, SVR (PCA)) methods. Furthermore, different LSTM structures were also investigated, with recurrent neural networks (RNN) based on 2019 data to determine the best structure. The following parameters of prediction accuracy measure were considered: RMSE, MSE, MAE, correlation (r) and determination (R2) coefficients. In comparison to all other approaches, RNN-LSTM had higher prediction accuracy on the basis of minimum (RMSE and MSE) and maximum (r and R2). The p-si, m-si and a-si PV plants showed the lowest RMSE values of 26.85 W/m2, 19.78 W/m2 and 39.2 W/m2 respectively. Moreover, the proposed method was found to be robust and flexible in forecasting the output power of the three considered different photovoltaic plants.
Publisher: American Society of Clinical Oncology (ASCO)
Date: 20-08-2023
DOI: 10.1200/JCO.23.00562
Abstract: Pirtobrutinib is a highly selective, noncovalent (reversible) Bruton tyrosine kinase inhibitor (BTKi). We report the safety and efficacy of pirtobrutinib in patients with covalent Bruton tyrosine kinase inhibitor (cBTKi) pretreated mantle-cell lymphoma (MCL), a population with poor prognosis. Patients with cBTKi pretreated relapsed/refractory (R/R) MCL received pirtobrutinib monotherapy in a multicenter phase I/II trial (BRUIN ClinicalTrials.gov identifier: NCT03740529 ). Efficacy was assessed in the first 90 consecutively enrolled patients who met criteria for inclusion in the primary efficacy cohort. The primary end point was overall response rate (ORR). Secondary end points included duration of response (DOR) and safety. The median patient age was 70 years (range, 46-87), the median prior lines of therapy was 3 (range, 1-8), 82.2% had discontinued a prior cBTKi because of disease progression, and 77.8% had intermediate- or high-risk simplified MCL International Prognostic Index score. The ORR was 57.8% (95% CI, 46.9 to 68.1), including 20.0% complete responses (n = 18). At a median follow-up of 12 months, the median DOR was 21.6 months (95% CI, 7.5 to not reached). The 6- and 12-month estimated DOR rates were 73.6% and 57.1%, respectively. In the MCL safety cohort (n = 164), the most common treatment-emergent adverse events (TEAEs) were fatigue (29.9%), diarrhea (21.3%), and dyspnea (16.5%). Grade ≥3 TEAEs of hemorrhage (3.7%) and atrial fibrillation/flutter (1.2%) were less common. Only 3% of patients discontinued pirtobrutinib because of a treatment-related adverse event. Pirtobrutinib is a first-in-class novel noncovalent (reversible) BTKi and the first BTKi of any kind to demonstrate durable efficacy after prior cBTKi therapy in heavily pretreated R/R MCL. Pirtobrutinib was well tolerated with low rates of treatment discontinuation because of toxicity.
Publisher: Massachusetts Medical Society
Date: 03-01-2019
No related grants have been discovered for Koji Izutsu.